Exhibit 99.1 THE NEXT EVOLUTION IN CELLULAR MEDICINE June 2022 Page 1
DISCLAIMERS Forward-Looking Statements This presentation contains certain “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements may include, but are not limited to, statements regarding Celularity’s expectations, hopes, beliefs, intentions or strategies regarding the future, including, without limitation, statements regarding: (i) the success and timing of cellular therapeutic development activities and initiating clinical trials, (ii) the success and timing of planned clinical trials, and regulatory submissions (iii) the ability to obtain and maintain regulatory approval of any therapeutic candidates, (iv) its plans to research, discover and develop additional therapeutic candidates, including by leveraging genetic engineering and other technologies and expanding into additional indications, (v) its ability to expand its manufacturing capabilities, and to manufacture its therapeutic candidates and scale production, (vi) its ability to meet the milestones set forth herein, and (vii) its future financial position and performance, business strategy, budgets, projected costs, plans, synergies and objectives of management for future operations, among others. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements and reflect various estimates and assumptions concerning anticipated result. Without limiting the foregoing, the words “believes,” “anticipates,” “continues”, “could”, “may”, “might”, “plans,” “expects,” “intends,” “estimated,” “forecasted,” “projection”, “possible”, “potential”, “predicted”, “projected”, “should”, “strive”, “would” and similar expressions identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements. Celularity’s actual results or performance may be materially different from that expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include risks related to risks associated with: developing cellular therapy candidates; ongoing and planned clinical trials; Celularity’s ability to obtain adequate financing; changes in applicable laws or regulations; third-party licenses, supply-chain or manufacturing challenges, strategic alliances or licensing arrangements; trends in the industry, changes in the competitive landscape, delays or disruptions due to the ongoing COVID-19 pandemic or other economic, business and/or competitive factors, including geopolitical factors, such as the recent Russian invasion of Ukraine. For a discussion of these and other risks, see “Risk Factors” in Celularity’s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Celularity owns or has the rights to various trademarks, service marks and trade names that it uses in connection with the operation of its business. This presentation may also contain trademarks, service marks, trade names and copyrights of third parties, which are the property of their respective owners. The use or display of third parties’ trademarks, service marks, trade names or products in this presentation is not intended to, and does not imply, a relationship with Celularity, or an endorsement or sponsorship by or of Celularity. Solely for convenience, the trademarks, service marks, trade names and copyrights referred to in this presentation may appear without the TM, SM, ® or © symbols, but such references are not intended to indicate, in any way, that Celularity will not assert, to the fullest extent under applicable law, their rights or the right of the applicable licensor to these trademarks, service marks, trade names and copyrights. Industry Data The data contained herein is derived from various internal and external sources and has not been independently verified by Celularity. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections or modeling or any other information contained herein. Certain information contained in this presentation relates to or is based on studies, publications, surveys and Celularity’s own internal estimates and research. Such estimates and research has not been verified by any independent source. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Trademarks, Service Marks and Trade Names Celularity owns or has the rights to various trademarks, service marks and trade names that it uses in connection with the operation of its business. This presentation may also contain trademarks, service marks, trade names and copyrights of third parties, which are the property of their respective owners. The use or display of third parties’ trademarks, service marks, trade names or products in this presentation is not intended to, and does not imply, a relationship with Celularity, or an endorsement or sponsorship by or of Celularity. Solely for convenience, the trademarks, service marks, trade names and copyrights referred to in this presentation may appear without the TM, SM, ® or © symbols, but such references are not intended to indicate, in any way, that Celularity will not assert, to the fullest extent under applicable law, their rights or the right of the applicable licensor to these trademarks, service marks, trade names and copyrights.
CELULARITY’S VISION To deliver innovative off-the-shelf allogeneic cellular medicines for patients with high unmet need at unparalleled scale, quality and cost. Lead the evolution in placental-derived therapeutics: advance the discovery of the placenta as a limitless, renewable source of neonatal cells, which are biologically preferred to cells from adult bone marrow or peripheral blood. Target large markets with high unmet need: broad therapeutic application including cancer, infectious, and degenerative diseases. Develop safe and effective therapies: leverage inherent advantages of placental-derived cells to produce uniform, scalable and optimized cellular medicines. Deliver off-the-shelf, affordable therapies: cryopreserved allogeneic cellular medicines and biomaterial products that clinicians can access on demand and off-the-shelf, enabling repeat dosing/multiple cycles as required in an outpatient setting. Page 3
CELULARITY: COMPANY HISTORY Celgene Spin-out (2017) Leveraging 20+ Years of Cellular Therapeutics Innovation Celularity and GX Acquisition IND Safe to Proceed Orphan Drug Designation Corp. Announced Merger CYNK-101 in for CYNK-101 in the FIH cryopreserved Agreement to Create a Publicly Company Ticker Advanced HER2/neu Treatment of Advanced allogeneic placental- Listed Leader in Allogeneic Updated to “CELU” Positive Gastric and HER2/neu Positive derived NK cell therapy Cellular Therapy on Nasdaq GEJ Cancers Gastric and GEJ Cancers program launched $100M Series (CYNK-001) B-1 Financing Fast Track Orphan Drug formed from Allogeneic Placental Placental Designation by Designation for Celgene Cell Pluripotent Cell T-cell/CAR-T Partnership with the FDA for CYNK-001 in the 1 program launched Therapeutics spin- program launched CYNK-001 in the Treatment of out (APPL-001) (CyCART-19) Treatment of AML Malignant Gliomas 2000 2016 2017 2018 2019 2020 2021 2022 $45M Series $210M Placental IND Safe to Genetically-modified Exclusive Strategic Preclinical Data on Multi-Year Strategic A Financing Series B Exosome Proceed NK cell therapy Partnership with CYNK-101 and Partnership with 2 Financing program CYNK-001 CAR-NK at the 63rd program launched launched in GBM ASH Annual Meeting (CYNK-101) (pExo) IND Safe to Proceed Fast Track Exclusive Supply and Preclinical Data Fast Track CYNK-001 in COVID-19 Designation by Distribution Agreement for on CYNK-101 at Designation by the the FDA for Multiple Commercial 36th SITC Annual FDA for CYNK-101 in 2000 – Anthrogenesis Corporation – Founded by Dr. Robert Hariri CYNK-001 in the Products with Meeting the Treatment of Treatment of Advanced HER2/neu 2002 – Anthrogenesis acquired by Celgene, becomes Celgene Cellular Therapeutics Recurrent GBM Positive Gastric and 2005 – Allogeneic Placental Mesenchymal-like Stromal Cells in Crohn’s, DFU GEJ Cancers 2014 – Celgene & Bluebird Bio Autologous CAR-T Collaboration 2015 – Celgene & Juno Therapeutics Autologous CAR-T collaboration KEY: CORPORATE MILESTONE CLINICAL MILESTONE FINANCIAL MILESTONE 2016 – FIH allogeneic placental-derived NK cell therapy product (Placental NK-007) 1, 2 Celularity continues to work with collaboration partners and may elect to provide updates at upcoming conferences. Page 4
CELULARITY PLACENTAL-DERIVED PRODUCT PLATFORM Capitalizing on the Benefits of Placental-Derived Cells to Target Multiple Diseases One Placenta à Many Patients Cryopreserved - On Demand T-Cell Isolation + Genetic Modification • Universal donor material & Off-The-Shelf • No requirement for matching • No immunogenicity or toxicity between a patient and donor • Re-dose\fine tune treatments NK CD 34+ Cell Isolation CELL • Absence of allo-antibodies THERAPY PLACENTA PRODUCTS NK CD34+ Cell Isolation + Genetic Modification Mesenchymal-like Stromal Cell Isolation 1 Donor Postpartum Placenta • Abundant, reliable, renewable and biologically consistent raw material • Nature’s ‘professional’ universal donor tissue • +140 Million Worldwide HEMATOLOGICAL SOLID DEGENERATIVE INFECTIOUS MALIGNANCIES TUMORS DISEASES DISEASE Greatest Degree of Natural Stemness • Greater proliferative performance (Cmax), and persistence • Greater natural immune tolerance 100-100K Doses/Placenta • High scalability Page 5
SINGLE-SOURCE, PLACENTA-BASED PLATFORM DRIVING BROAD PIPELINE 4 Key Cell Types Driving 6 Clinical Indications and Potential for Broad Expansion SINGLE SOURCE 4 ALLOGENEIC 4 KEY PROGRAMS 6 INITIAL INDICATIONS MATERIAL CELL TYPES Placental CyCART-19 B-Cell Malignancies CAR-T AML CYNK-001 Unmodified NK (cryopreserved) Glioblastoma Multiforme Placenta CYNK-101 HER2+ Gastric Cancer Genetically Modified NK CD16VP+ mAb Crohn’s Placental Mesenchymal- APPL-001/ PDA-002 like Stromal Cells FSHD = INITIAL INDICATIONS OF FOCUS MANUFACTURING >> Purpose-built, fully integrated manufacturing facility; rapidly scalable, end-to-end supply chain P Page age 6 6
MANUFACTURING OVERVIEW Fully Integrated, Purpose-Built Commercial Scale Manufacturing Site Including Translational Research & Biorepository PURPOSE BUILT FACILITY FOR STAFFED BY OVER 100 HIGHLY COMMERCIAL SCALE, GMP-READY COMMERCIAL-SCALE CELLULAR SPECIALIZED SCIENTISTS, ENGINEERS THERAPEUTIC MANUFACTURING & TECHNICIANS § 9 Grade C/ISO 7 suites § Optimized, product-specific CMC, QA/QC and § 6 Grade D/ISO 8 labs § $80M investment in cGMP/cGTP manufacturing manufacturing processes accelerate product § Enables greater control, efficiency and development, production and commercialization§ Dedicated translational research labs optimization than is achievable by outsourcing to contract manufacturing organizations (CMOs) § Over 2 decades of experience with source material alone procurement Celularity benefits from Celgene’s 20 year+ investment in developing the technologies and capabilities required to manufacture cellular products at scale with consistent and reliable quality Page 7
OUR EXPERIENCED LEADERSHIP TEAM With Deep Expertise in Cell Therapy Executive Leadership Team David Bradley Glover, Anne Jones, Robert J. Hariri, Andrew Pecora, John Dr. Stephen Keary Beth MD, PhD MD, FACP, CPE Haines Beers PhD PhD Brigido Dunn, Esq. Steinbrenner President Chief Financial Chief Technology Chief Business President, Founder, Chairman Chief Operating EVP & General EVP, Human Officer Officer Officer Degenerative Diseases Officer Counsel Resources & CEO Anthrogenesis C O R P O R A T I O N Page 8
CLINICAL PIPELINE Overview Placental Derived Program Indication Preclinical IND Submission Phase I Phase II Cell Type Acute Myeloid Leukemia (AML) Unmodified CYNK-001 Natural Killer Cell Glioblastoma Multiforme (GBM) ONCOLOGY Genetically CYNK-101 HER2+ Modified + mAb Gastric Cancer Natural Killer Cell B-Cell CAR-T CYCART-19* Malignancies Crohn’s APPL-001 Disease DEGENERATIVE Placental Mesenchymal- DISEASES like Stromal Cells Facioscapulohumeral Muscular Dystrophy PDA-002 (FSHD) *includes technology in-licensed from Sorrento Therapeutics, Inc. Page 9
Cell Characterization
THE PLACENTA IS ENRICHED FOR NAÏVE/SCM T CELLS COMPARED TO HEALTHY DONOR PERIHPERAL BLOOD ENABLING PRODUCTION OF CAR-T CELLS WITH GREATER ACTIVITY IN ANIMAL MODELS Placenta T cell starting material contains similar CD4/CD8 ratio as healthy adult blood T cells PBMC T Placenta T Stem Cell Central Effector Marker Naïve Memory Memory Memory CD45RA + + - +/- CD27 +++ +++ ++ +/- CCR7 +++ +++ ++ - CD28 ++ +++ +++ +/- Telomere +++ +++ ++ + The primary T cell population in placenta are T and Self-renewal + +++ ++ + N T which retain the greatest proliferative potential IFN-γ - + ++ +++ SCM IL-2 - ++ +++ +/- Cytotoxicity - +/- + +++ Adopted from Gattinoni et al. Nature Reviews Cancer 2012 PBMC T Placenta T P Page age 11 11 Function Phenotype
CYCART-19 (PLACENTAL CAR-T) RETAINED STEMNESS VS PBMC CD19 CAR-T POST MANUFACTURING Our process uses CRISPR to knockout CYCART-19 cells had better retention of the TRAC and transduction of CD19-CAR T population following manufacturing SCM PBMC CD19 CAR-T CYCART-19 PBMC CD19 CAR-T CYCART-19 CYCART-19 cells yielded a preferable CYCART-19 had longer telomeres, resisted expression of CD4/CD8 CAR-T cell ratio closer to 1:1 senescence marker CD57 and checkpoint inhibitor LAG3 PBMC CD19 CAR-T CYCART-19 PBMC CD19 CAR-T CYCART-19 P Page age 12 12
CYCART-19 SECRETED HIGH LEVELS OF IL-2 AS COMPARED TO PBMC DERIVED CAR-T, CONFERRING A POTENTIAL CAR-T CELL SURVIVAL AND PROLIFERATION BENEFIT CYCART-19 and PBMC CD19-CART were similarly cytotoxic CD4 and CD8 CYCART-19 cells strongly expressed IL-2 PBMC CD19 CAR-T CYCART-19 NT PBMC T NT CYCART CYCART-19 secreted high levels of IL-2 and low levels of IFNγ following stimulation by CD19+ lymphomas PBMC CD19 CAR-T CYCART-19 • Enhanced Intrinsic IL-2 production is expected to help sustain CYCART-19 survival, proliferation, resist exhaustion, and maintain persistence in vivo – M. Kahan et al, Science Immunology 2022 • Reduced IFNγ production by CYCART-19, is expected to limit local PD-L1 upregulation, which may mitigate severity of CRS P Page age 13 13 CD19 CAR-T CD19 CAR-T + NALM6 + Daudi
CYNK-001 AML and GBM
CYNK-001(unmodified NK cellular therapy) Overview RATIONALE NK CELL THERAPIES § NK cells are natural immune cells that eradicate both cancer and virus- infected cells ADULT CELULARITY Cell Therapy DONOR CYNK-001 & – Key mediators of antibody-dependent cellular cytotoxicity (ADCC) Technology Scorecard DERIVED CYNK-101 § Placental-derived NK cells exhibit: Source Procurement Non-invasive Collection / Reliable – distinct, maturation and activation states PP Procurement – an immature phenotype Lower COGs – longer telomere length in comparison to PB NK cells, which suggests Standardized, Scalable PP Manufacturing high in vivo proliferation and persistence Starting Material PP Consistent Quality and Phenotype KEY HIGHLIGHTS CYNK-001 (unmodified NK cellular therapy) Ability to Readily Expand While Maintaining a Less OP § Preclinical data support anticancer activity against a range of hematological Differentiated Phenotype malignancies and solid tumors § Phase 1 trial in relapsed/refractory (r/r) AML showed early signs of clinical “Off-the-Shelf” Treatment PP benefit and a generally positive safety profile § Estimated trial completion in 2023 Ability to Re-dose Patients OP § Anticipated BLA in 2025 for AML (if Necessary) § Anticipated BLA To Be Determined for GBM Page 15 MANUFACTURING COMPLEXITY
PERSISTENCE, MATURATION AND PROLIFERATION WITH ABSENCE OF ALLO-HLA ANTIBODIES PNK-007 demonstrated persistence Persistent PNK-007 cells up to 28 days (mean=11days) matured and proliferated No detectable exhaustion PNK-007 demonstrated Absence of allo-HLA on PNK-007 cells effector function post infusion antibodies in all subjects H L A -A/B/C P an el R ea ctiv e A n tib o d y T est (+ ) co n tro l (-) co n tro l scr e e n in g D ay 0 D ay 7 D ay 14 D ay 21 D ay 28 F IT C G eom . M ean Source: AACR 2019 poster: Immune monitoring of CYNK-001, an allogeneic, off the shelf NK cell in a Phase I study of acute myeloid leukemia”, Celularity data; *CYNK-001 is a P Page age 16 16 comparable cryopreserved formulation of PNK-007, the product used in this study 0 10 0 20 0 30 0 40 0 50 0 60 0
CYNK-001 AML
CYNK-001-AML-001 (MRD+ AND RELAPSED REFRACTORY AML) Phase 1 Study Schema – Trial in progress Enrolling Cohort 4a: Cohort 5a: Cohort 6a: Cohort 7a: EXPANSION COHORT AML MRD+ AML MRD+ AML MRD+ AML MRD+ AML MRD+ (N=4) Lymphodepletion Regimen #1 1.8B x3 1.8B x3 1.8B x 4 3B x 4 (12B) MTD/MPD of CYNK (5.4B) (5.4B) + IL2* (7.2B) + IL2* + IL2* +/- IL2* Cohort 2: Cohort 3: Cohort 1: AML MRD+ AML MRD+ AML MRD+ Lymphodepletion Regimen #2 1.2B Cells 1.8B Cells of 600M Cells of CYNK* CYNK* of CYNK* Cohort 5b: Cohort 6b: Cohort 7b: EXPANSION COHORT Cohort 4b: R/R AML R/R AML R/R AML R/R AML R/R AML (N=4) 1.8B x3 1.8B x 3 1.8B x 4 3B x 4 (12B) MTD/MPD of CYNK (5.4B) (5.4B) + IL2* (7.2B) + IL2* + IL2* +/- IL2* * CYNK-currently given on Days 0, 7,14 and D21 (for cohorts 6 & 7) LD Regimen #2 LD Regimen #1 For Cohorts with IL-2 – Dose 6M IU on Days 0,2,4,7,9,11,14 & D21 (cohorts 6 & 7) Lymphodepletion Lymphodepletion for Cohorts 1 to 3 for Cohorts 4 to 6 • Developed an enhanced Lymphodepletion Regimen implemented in cohort 4, which enables safe outpatient administration (Days -5, -4, -3) (Days -6, -5, -4, -3) and results in adequate IL-15 serum levels and maximum suppression of T regulatory cells. This enables co-administration of IL-2 to promote CYNK-001 expansion, persistence and potency for over 21 days. Cyclophosphamide Cyclophosphamide 300 mg/m2/day 900 mg/m2/day • CYNK-001 is generally well-tolerated with evidence of a dose effect and biologic activity as demonstrated with CR’s in some & Fludarabine & Fludarabine patients. 25 mg/m2/day 30 mg/m2/day th MESNA • From cohort 6, we plan to add IL-2, add a 4 dose of cells on day 21 and potentially increase the dose to 3 Billion CYNK- 001 cells/infusion given the window of dosing opportunity observed in our translational studies. Page 18
AML PATIENT OUTCOMES DATA SUMMARY – RELAPSED REFRACTORY AML Evidence of a dose effect of CYNK-001 LD Doses: Risk Group / Cell Dose Blast Patient ID Cytoxan/ Day 28 Day 60 Day 120 Day 180 Day 300 Age (yrs) / IL2 Pre-LD Fludarabine 002-1001 Poor/adverse / 70 8400 mg / 230 mg 70 Million 82.2% > 82.2% Died 006-1002 Poor/adverse / 61 8400 mg / 230 mg 70 Million > 10% > 10% Died 002-1003 Intermediate / 67 8400 mg / 230 mg 70 Million 89% 49% Died 007-1001 Poor/adverse / 30 8400 mg / 230 mg 240 Million 52% > 52% Died 001-1002 Poor/adverse / 59 8400 mg / 230 mg 240 Million 2% 25% Died 007-1002 Poor/adverse / 65 8400 mg / 230 mg 240 Million 15% > 15% Died 001-1003 Poor/adverse / 70 8400 mg / 230 mg 700 Million 9.7% 12% Died 002-1004 Poor/adverse / 69 8400 mg / 230 mg 700 Million 6% 1% (CRp) Died 006-1004 Intermediate / 63 8400 mg / 230 mg 700 Million 30% Died Day 18 008-1001 Poor/adverse / 66 8400 mg / 230 mg 700 Million 7% 0% (MLFS) Died CR – post allo-HSCT 106-0005 Poor/adverse / 71 6624 mg / 221 mg 5.4 Billion 8.4% 0.8% (MLFS) 103-0006 Poor/adverse / 67 6624 mg / 221 mg 5.4 Billion 21% Died Day 15 Intermediate / 62 6624 mg / 221 mg 101-0009 5.4 Billion 11% 0.096% (MLFS) 0.57% CR= Complete remission, CRp = Complete remission with incomplete platelet recovery, MLFS: Morphologic Leukemia Free State P Page age 19 19
AML PATIENT OUTCOMES DATA SUMMARY – MRD AML Evidence of a dose effect of CYNK-001 LD Doses: Risk Group/ Cell Dose Blast Patient ID Cytoxan/ Day 28 Day 60 Day 120 Day 180 Day 300 Age (yrs) / IL2 Pre-LD Fludarabine Intermediate / 75 1656 mg / 138 mg 1.8 Billion 0.87% 0.54% 0.42% 0.18% 1.6% 1.9% 102-0001 101-0001 Intermediate / 51 1656 mg / 138 mg 3.6 Billion 0.007% 2.8% 30.9% Died 101-0002 Intermediate / 58 1656 mg / 138 mg 3.6 Billion 0.78% 0.19% 29.3% Intermediate/ 66 1656 mg / 138 mg 101-0003 3.6 Billion 2.6% 1.7% 12.2% 106-0003 Intermediate / 62 1656 mg / 138 mg 5.4 Billion 0.52% 0.72% Intermediate / 62 1656 mg / 138 mg 5.4 Billion 1.2% 0.013% 0.47% 8.2% 106-0004 101-0007 Intermediate /76 1656 mg / 138 mg 5.4 Billion 4.3% 23.1% 101-0008 Intermediate / 69 6624 mg / 221 mg 5.4 Billion 3.4% 0.53% 6.8% Page 20
CYNK-001 GBM
CYNK-001-GBM-002 (GLIOBLASTOMA PROGRAM) Planned Phase 1 Dose Escalation / Phase 2 Proof of Concept Screening Cohort 1 Up to 28 days Intravenous Intracavitary Resection recurrent resection eligible GBM 9 6 (2.4 x10 cells – D1,D8,D15) (100x10 cells – (3 out of 4 wks) Cohort 2 Lymphodepletion Intravenous Intracavitary Resection 9 6 (Days -5, -4, -3) (200x10 cells – (3 out of 4 wks) (2.4 x10 cells – D1,D8,D15) Cyclophosphamide 2 900 mg/m /day Cohort 3 Fludarabine Intravenous Intracavitary Resection 2 9 6 30 mg/m /day (3.6 x10 cells – D1,D8,D15) (200x10 cells – (3 out of 4 wks) *IC - intracavitary MESNA Additional IC* cycles Cohort 4 Additional 3 cycles Intravenous Intracavitary Resection 6 (200x10 cells – (3 out of 4 wk cycles) 6 (MTD – D1,D8,D15) (200x10 cells – (3 out of 4 wks) Phase 1 Dose Escalation Phase 2 Proof of Concept • N = ~ 21 patients • N = ~ 45 patients (80% Power - Target 35% 6-month PFS) • North American sites (~5 sites) • North American sites (5 - 10 sites) • Primary Endpoints: Safety, Feasibility and Tolerability (42 • Primary Endpoints: Overall Survival (OS) Day DLT period) • Secondary Endpoints: PFS, ORR post resection • Secondary Endpoints: Progression Free Survival (PFS) • Exploratory Endpoints: NK cell persistence and trafficking P Page age 22 22
CYNK-101 HER2+ Advanced Esophageal / Gastric Adenocarcinoma
CYNK-101 (modified NK cellular therapy) IN HER2+ GASTRIC CANCER Overview RATIONALE § Engineering CYNK cells with high affinity and cleavage resistant (CD16VS) Antibody-Dependent Cellular Cytotoxicity expected to improve affinity for IgG1 therapeutic antibodies, resist Target Recognition activation induced cleavage and improve overall ADCC potential Lysis KEY HIGHLIGHTS Antibody § CYNK-101 adds “punching power” to the CYNK-001 platform via genetic modification Tumor Cell NK cell § Enable combination therapy with ADCC mediating therapeutic monoclonal CD16VS antibody (mAb) therapies Tumor Antigens − When combined with Trastuzumab demonstrates ADCC activity against HER2+ Gastric Cancer cells CD16VS - high-affinity cleavage-resistant CD16 − Joint impact of modified NK cells + mAb shows improved immunologic response with added NK cell killing § Anticipated BLA To Be Determined for HER2+ Gastric Cancer P Page age 24 24
CYNK-101 DEMONSTRATED ANTITUMOR ACTIVITY Against Gastric Cancer Cell Lines in Conjunction with Anti-HER2 Monoclonal Antibody NCI-N87 E/T 2:1 RESULTS Target cells alone • Significant ADCC activity of CYNK-101 in combination with Trastuzumab against both gastric cancer cell lines was shown at E:T ratio of 2:1 over 24h in comparison with that of CYNK CYNK-101 + IgG Non-Transduced (NT) or IgG control CYNK-NT + IgG CYNK-NT + Trastuzumab CYNK-101 + Trastuzumab OE19 E/T 2:1 CONCLUSION Target cells alone • Demonstrated ADCC activity of CYNK-101 in combination with Trastuzumab against HER2+ CYNK-101 + IgG gastric cancer cells CYNK-NT + IgG – HER2+ Gastric demonstrated to be an CYNK-NT + Trastuzumab immunologically susceptible tumor type with CYNK-101 + Trastuzumab evidence of strong NK cell infiltration Source: Celularity Data P Page age 25 25 Killing Killing Index Index
CYNK-101 PROVIDES A BACKBONE FOR COMBINATION THERAPIES Enhanced ADCC with Multiple Antibodies Forms the Basis of Potential Combination Therapies ADCC WITH RITUXIMAB ADCC WITH ELOTUZUMAB ADCC WITH DARATUMUMAB E:T Ratio (Against Daudi) CYNK-101 + mAb CYNK + mAb CYNK-101 + IgG CYNK + IgG • Improved ADCC response observed from CYNK-101 compared to unmodified CYNK cells against lymphoma cell lines in combination with: Rituximab, Daratumumab and Elotuzumab antibodies • IND-enabling studies on-going to evaluate CYNK-101 + mAbs in subcutaneous and orthotopic tumor models P Page age 26 26 % Specific Lysis % Specific Lysis % Specific Lysis
CYNK-101-HER2-001 (HER2+ GASTRIC/GEJ CANCER) Planned Phase 1 - Dose Escalation / Phase 2a Expansion/Proof of Concept Maintenance Induction NK Cell Re- Induction (every 21 days) (5 cycles every 21 days) Pembrolizumab Lymphodepletion 200 mg (Day 1 of cycle) Pembrolizumab CR, PR, Pembrolizumab (3 days) 200 mg (Day 1 of cycle) 200 mg q 3 weeks Trastuzumab SD, PD 6 mg/kg (Day 1 of cycle) Cyclophosphamide Trastuzumab Trastuzumab 2 900 mg/m /day 6 mg/kg (Day 1 of cycle) 8 mg/kg (initial) IL-2 (6M IU) 6 mg/kg (after initial) (Days 1, 8, 15 of cycle) Fludarabine IL-2 (6M IU) (IL-2 administered 1 - 3 2 30 mg/m /day (IL-2 administered 1 - 3 Chemotherapy hours before CYNK) hours before CYNK) platinum MESNA containing CYNK-101 CYNK-101 chemotherapy (Days 1, 8, 15 of cycle) (Day 1 of cycle) Phase 1: Dose Escalation (n = up to 15 patients) Phase 2a: Expansion/Proof of Concept (n = ~40 patients) • Primary Endpoints: Determine safety and maximum tolerated dose • Primary Endpoints: ORR (CR+PR) (>65%-80%) • Secondary Endpoints: Various Efficacy measures • Secondary Endpoints: (For patients that are CR, PR and SD) – Landmark PFS at 6 months & 12 months (CR, PR and SD) Dosing Cohorts – Duration of Response (CR and PR) – Incidence of response conversion (PR and SD) CYNK-101 CYNK-101 – ORR for patients after initial induction are PD Re-Induction Dosing Maintenance Dosing – Safety 9 9 Cohort -1: 1.8 x 10 cells Cohort -1: 1.8 x 10 cells • Maintenance Dosing 9 9 – Patients in CR after CYNK-101 to dose an additional 2 cycles of NK cells combination Cohort 1: 3.6 x 10 cells Cohort 1: 3.6 x 10 cells 9 9 – Patients in PR/SD after CYNK-101 to dose until CR or Progression Cohort 2: 7.2 x 10 cells Cohort 2: 3.6 x 10 cells – Patients in PD after CYNK-101 to discontinue to from study Page 27 SCREENING (UP TO 28 DAYS) Disease Status
CyCART-19 B-Cell Malignancies
CYCART-19 OVERVIEW Celularity Approach and Advantages RATIONALE CAR-T THERAPIES • Rationale for greater stemness, expandability, persistence CELL THERAPY • Abundant renewable starting cell source for allogeneic therapies OTHER CELULARITY TECHNOLOGY AUTOLOGOUS ALLOGENEIC CYCART-19 SCORECARD • Potential for improved safety profile due to immunological naivety Source Procurement Non-invasive Collection / OOP Reliable Procurement KEY HIGHLIGHTS • Celularity has established a robust process to obtain placental T naive/scm Lower COGs Standardized, Scalable OPP population as source materials to produce off-the-shelf, highly scalable Manufacturing CYCART-19 cells Starting Material • CYCART-19 has shown stem cell memory characteristics as evidenced by Consistent Quality and OOP greater in vivo persistence and durable antitumor activity in preclinical models Phenotype • Strong pre-clinical evidence of anti-tumor activity Ability to Readily Expand – CYCART-19 cells outperformed adult blood-derived CAR-T cells by OOP While Maintaining a Less showing significantly greater persistence and longer survival in preclinical Differentiated Phenotype studies “Off-the-Shelf” • Early data have not shown signs of GvHD OPP Treatment • IND submitted in first quarter of 2022 and pending resolution of additional questions from FDA, expect to commence Phase 1/2 clinical trial in second Ability to Re-dose Patients OPP half of 2022 (if Necessary) • Note: If Phase 1 successful, Celularity plans to pursue a Phase 2 basket trial across major B-cell malignancies (subject to FDA discussions) • Anticipated BLA To Be Determined for CYCART-19 P Page age 29 29 MANUFACTURING COMPLEXITY
CYCART-19-BCM-001 (RELAPSED/REFRACTORY B-CELL MALIGNANCIES) Planned Phase 1 / Phase 2 Phase 1 Phase 2: Safety and Dose Finding Cohorts Cohort A: High Grade NHL Dose Level 1: CD-19 targeted therapy naïve (n= ~66) 6 40 x10 cells • DLBCL N=3 • High Grade B-Cell lymphoma • Primary mediastinal B-Cell lymphoma • Transformed follicular lymphoma Dose Level 2 • Mantle cell De-Escalation: • Burkitt lymphoma/leukemia 6 • Any B-Cell malignancy with Secondary CNS involvement 80 x10 cells N=3 Cohort B: Low Grade NHL Lymphodepletion: Screening & CD-19 targeted therapy naïve (n= ~66) Enrollment: 2 Dose Level 2: CY 900 mg/m • Follicular 2 Flu 30 mg/m 6 120 x10 cells • Marginal Cell R/R CD19+ Mesna N=3 • CLL/SLL B-cell Days -5, -4, -3 • Waldenström’s macroglobulinemia malignancies (Days -2, -1: no treatment) • Any other low grade NHL subtypes Dose Level 3 De-Escalation: 6 Cohort C: Any Grade NHL 240 x10 cells CD-19 targeted therapy exposed N=3 (n= ~66) Dose Level 3: Cohort D: Primary Central Nervous 6 360 x10 cells System Lymphoma N=3 (n= ~74) P Page age 30 30
Appendix Additional Detail
CELULARITY IMPACT™ PLATFORM Broad IP Protection Across All Lead Programs PNK Broad Background Patent Process Patents 15 PATENT PLACENTAL NK Genetically Modified PNK Patents Treatment of AML & MM FAMILIES Cryopreserved PNK (CYNK-001) Patents Treatment of GBM Process Patents Cryopreserved Genetically Modified PNK Product Characterization Patents (CYNK-101) Patents Cryopreserved Genetically Modified PNK (CYNK-101) Patents 2 PATENT PLACENTAL CAR-T FAMILIES Early CAR Receptor Technology CAR Receptor Method & Composition Celularity Placental CAR-T Patents Anti-CD19 CAR Receptor Product Characterization PLACENTAL-DERIVED Product Characterization & 25 PATENT Method of Production MESENCHYMAL-LIKE FAMILIES APPL/PDAC Patents STROMAL CELLS Product Description & Indication Patents P Page age 32 32 PLACENTAL-DERIVED CELLULAR PLATFORMS
CELULARITY IMPACT™ PLATFORM The Placenta as a Renewable Allogeneic Source, with Purpose-Built Commercial Scale Manufacturing PROCESSES PRODUCTS INDICATION Acute Myeloid Leukemia Lymphocytic Progenitors CYNK-001 Glioblastoma Multiforme CD34+ Cells Placental NK Gastric Cancer Lymphocytic Progenitors Genetic Modification CYNK-101 (Herceptin) Mononuclear Cell B-Cell Malignancies CAR Transduction Gene Editing Separation/ CyCART-19 Placental CAR-T (CD19) T Cell Isolation Mesenchymal- Placental Master Cell Genetic Working Cell Crohn’s Disease like Stromal APPL-001 Bank Modification Stock Pluripotent Cells P Page age 33 33 PLACENTAL-DERIVED CELLULAR PLATFORMS
MANUFACTURING PROCESS Celularity Purpose-built Commercial Scale 150,000 sq. ft. Manufacturing Facility Network of Longstanding Cell Isolation and Partnerships Selection Product Cryopreservation • Birthing Centers • Proprietary perfusion • In-process cooling/cryopreservation • Obstetricians methodology of drug product • Academic Hospitals • Removal of vascular/ • In-house cryostorage facility with – Controllable and scalable circulatory blood 24/7 monitoring on-demand birthing material • Cell suspension/separation • Long term storage readiness – Supports multiple • Cell selection/sorting for • Cold-chain logistics and distribution expertise products/programs hematopoietic, progenitor, • Cold-chain monitoring and traceability Cell Manufacturing and T-cells. • Cryopreserved donor stock • Controllable and flexible manufacturing Controlled Courier • Cell seeding, expansion and System differentiation • Procurement Kits • Cell harvesting & formulation • Temperature tracking • Use of automation (i.e., • Unique barcoding/labeling bioreactors, etc.) • Traceability from birthing • Highly scalable center to Celularity through manufacturing & distribution Delivery to Patients Tissue Manufacturing • Multiple commercial products Collection & Documentation with (30+ SKUs) of Donor Information • Multiple suite allocation allows for rapid increase in product • Qualified donors/Donor manufacturing eligibility • Multiple shift manufacturing • Informed consent • In house packaging capability • Detailed maternal and family • Ambient product storage health questionnaire • Long product shelf life/expiry • Completed delivery information • Comprehensive data set on donor and cell source P Page age 34 34